Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms

Chih Cheng Chen, Jie Yu You, Jrhau Lung, Cih En Huang, Yi Yang Chen, Yu Wei Leu, Hsing Ying Ho, Chian Pei Li, Chang Hsien Lu, Kuan Der Lee, Chia Chen Hsu, Jyh Pyng Gau

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3’-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3’-untranslated region has been shown to exhibit a myeloproliferative phenotype. To decipher the let-7-HMGA2 axis in myeloproliferative neoplasms, we employed an in vitro model supplemented with clinical correlation. Ba/F3 cells with inducible JAK2V617F expression (Ton.JAK2.V617F cells) showed upregulation of HMGA2 with concurrent let-7a repression. Ton.JAK2.V617F cells treated with a let-7a inhibitor exhibited further escalation of Hmga2 expression, while a let-7a mimic diminished the Hmga2 transcript level. Hmga2 overexpression conferred JAK2-mutated cells with a survival advantage through inhibited apoptosis. A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner. In samples from 151 patients with myeloproliferative neoplasms, there was a modest inverse correlation between the expression levels of let-7a and HMGA2. Overexpression of HMGA2 was detected in 29 (19.2%) of the cases, and it was more commonly seen in patients with essential thrombocythemia than in those with polycythemia vera (26.9% vs. 12.7%, P=0.044). Patients with upregulated HMGA2 showed an increased propensity for developing major thrombotic events, and they were more likely to harbor one of the 3 driver myeloproliferative neoplasm mutations in JAK2, MPL and CALR. Our findings suggest that, in a subset of myeloproliferative neoplasm patients, the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes.

Original languageEnglish
Pages (from-to)509-518
Number of pages10
JournalHaematologica
Volume102
Issue number3
DOIs
Publication statusPublished - Feb 28 2017
Externally publishedYes

Fingerprint

AT-Hook Motifs
Phenotype
Neoplasms
3' Untranslated Regions
Apoptosis
Essential Thrombocythemia
Polycythemia Vera
MicroRNAs
Transgenic Mice
Transcription Factors
Up-Regulation
Down-Regulation
Mutation
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Chen, C. C., You, J. Y., Lung, J., Huang, C. E., Chen, Y. Y., Leu, Y. W., ... Gau, J. P. (2017). Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. Haematologica, 102(3), 509-518. https://doi.org/10.3324/haematol.2016.154385

Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. / Chen, Chih Cheng; You, Jie Yu; Lung, Jrhau; Huang, Cih En; Chen, Yi Yang; Leu, Yu Wei; Ho, Hsing Ying; Li, Chian Pei; Lu, Chang Hsien; Lee, Kuan Der; Hsu, Chia Chen; Gau, Jyh Pyng.

In: Haematologica, Vol. 102, No. 3, 28.02.2017, p. 509-518.

Research output: Contribution to journalArticle

Chen, CC, You, JY, Lung, J, Huang, CE, Chen, YY, Leu, YW, Ho, HY, Li, CP, Lu, CH, Lee, KD, Hsu, CC & Gau, JP 2017, 'Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms', Haematologica, vol. 102, no. 3, pp. 509-518. https://doi.org/10.3324/haematol.2016.154385
Chen, Chih Cheng ; You, Jie Yu ; Lung, Jrhau ; Huang, Cih En ; Chen, Yi Yang ; Leu, Yu Wei ; Ho, Hsing Ying ; Li, Chian Pei ; Lu, Chang Hsien ; Lee, Kuan Der ; Hsu, Chia Chen ; Gau, Jyh Pyng. / Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. In: Haematologica. 2017 ; Vol. 102, No. 3. pp. 509-518.
@article{f73ac232c6954e6a886bc2245cf34afb,
title = "Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms",
abstract = "High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3’-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3’-untranslated region has been shown to exhibit a myeloproliferative phenotype. To decipher the let-7-HMGA2 axis in myeloproliferative neoplasms, we employed an in vitro model supplemented with clinical correlation. Ba/F3 cells with inducible JAK2V617F expression (Ton.JAK2.V617F cells) showed upregulation of HMGA2 with concurrent let-7a repression. Ton.JAK2.V617F cells treated with a let-7a inhibitor exhibited further escalation of Hmga2 expression, while a let-7a mimic diminished the Hmga2 transcript level. Hmga2 overexpression conferred JAK2-mutated cells with a survival advantage through inhibited apoptosis. A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner. In samples from 151 patients with myeloproliferative neoplasms, there was a modest inverse correlation between the expression levels of let-7a and HMGA2. Overexpression of HMGA2 was detected in 29 (19.2{\%}) of the cases, and it was more commonly seen in patients with essential thrombocythemia than in those with polycythemia vera (26.9{\%} vs. 12.7{\%}, P=0.044). Patients with upregulated HMGA2 showed an increased propensity for developing major thrombotic events, and they were more likely to harbor one of the 3 driver myeloproliferative neoplasm mutations in JAK2, MPL and CALR. Our findings suggest that, in a subset of myeloproliferative neoplasm patients, the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes.",
author = "Chen, {Chih Cheng} and You, {Jie Yu} and Jrhau Lung and Huang, {Cih En} and Chen, {Yi Yang} and Leu, {Yu Wei} and Ho, {Hsing Ying} and Li, {Chian Pei} and Lu, {Chang Hsien} and Lee, {Kuan Der} and Hsu, {Chia Chen} and Gau, {Jyh Pyng}",
year = "2017",
month = "2",
day = "28",
doi = "10.3324/haematol.2016.154385",
language = "English",
volume = "102",
pages = "509--518",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "3",

}

TY - JOUR

T1 - Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms

AU - Chen, Chih Cheng

AU - You, Jie Yu

AU - Lung, Jrhau

AU - Huang, Cih En

AU - Chen, Yi Yang

AU - Leu, Yu Wei

AU - Ho, Hsing Ying

AU - Li, Chian Pei

AU - Lu, Chang Hsien

AU - Lee, Kuan Der

AU - Hsu, Chia Chen

AU - Gau, Jyh Pyng

PY - 2017/2/28

Y1 - 2017/2/28

N2 - High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3’-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3’-untranslated region has been shown to exhibit a myeloproliferative phenotype. To decipher the let-7-HMGA2 axis in myeloproliferative neoplasms, we employed an in vitro model supplemented with clinical correlation. Ba/F3 cells with inducible JAK2V617F expression (Ton.JAK2.V617F cells) showed upregulation of HMGA2 with concurrent let-7a repression. Ton.JAK2.V617F cells treated with a let-7a inhibitor exhibited further escalation of Hmga2 expression, while a let-7a mimic diminished the Hmga2 transcript level. Hmga2 overexpression conferred JAK2-mutated cells with a survival advantage through inhibited apoptosis. A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner. In samples from 151 patients with myeloproliferative neoplasms, there was a modest inverse correlation between the expression levels of let-7a and HMGA2. Overexpression of HMGA2 was detected in 29 (19.2%) of the cases, and it was more commonly seen in patients with essential thrombocythemia than in those with polycythemia vera (26.9% vs. 12.7%, P=0.044). Patients with upregulated HMGA2 showed an increased propensity for developing major thrombotic events, and they were more likely to harbor one of the 3 driver myeloproliferative neoplasm mutations in JAK2, MPL and CALR. Our findings suggest that, in a subset of myeloproliferative neoplasm patients, the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes.

AB - High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3’-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3’-untranslated region has been shown to exhibit a myeloproliferative phenotype. To decipher the let-7-HMGA2 axis in myeloproliferative neoplasms, we employed an in vitro model supplemented with clinical correlation. Ba/F3 cells with inducible JAK2V617F expression (Ton.JAK2.V617F cells) showed upregulation of HMGA2 with concurrent let-7a repression. Ton.JAK2.V617F cells treated with a let-7a inhibitor exhibited further escalation of Hmga2 expression, while a let-7a mimic diminished the Hmga2 transcript level. Hmga2 overexpression conferred JAK2-mutated cells with a survival advantage through inhibited apoptosis. A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner. In samples from 151 patients with myeloproliferative neoplasms, there was a modest inverse correlation between the expression levels of let-7a and HMGA2. Overexpression of HMGA2 was detected in 29 (19.2%) of the cases, and it was more commonly seen in patients with essential thrombocythemia than in those with polycythemia vera (26.9% vs. 12.7%, P=0.044). Patients with upregulated HMGA2 showed an increased propensity for developing major thrombotic events, and they were more likely to harbor one of the 3 driver myeloproliferative neoplasm mutations in JAK2, MPL and CALR. Our findings suggest that, in a subset of myeloproliferative neoplasm patients, the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=85014494195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014494195&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.154385

DO - 10.3324/haematol.2016.154385

M3 - Article

C2 - 28057739

AN - SCOPUS:85014494195

VL - 102

SP - 509

EP - 518

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -